Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial
Open Access
- 21 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 224 (6), 967-975
- https://doi.org/10.1093/infdis/jiab330
Abstract
Early convalescent plasma transfusion may reduce mortality in patients with nonsevere coronavirus disease 2019 (COVID-19). This study emulates a (hypothetical) target trial using observational data from a cohort of US veterans admitted to a Department of Veterans Affairs (VA) facility between 1 May and 17 November 2020 with nonsevere COVID-19. The intervention was convalescent plasma initiated within 2 days of eligibility. Thirty-day mortality was compared using cumulative incidence curves, risk differences, and hazard ratios estimated from pooled logistic models with inverse probability weighting to adjust for confounding. Of 11 269 eligible person-trials contributed by 4755 patients, 402 trials were assigned to the convalescent plasma group. Forty and 671 deaths occurred within the plasma and nonplasma groups, respectively. The estimated 30-day mortality risk was 6.5% (95% confidence interval [CI], 4.0%–9.7%) in the plasma group and 6.2% (95% CI, 5.6%–7.0%) in the nonplasma group. The associated risk difference was 0.30% (95% CI, −2.30% to 3.60%) and the hazard ratio was 1.04 (95% CI, .64–1.62). Our target trial emulation estimated no meaningful differences in 30-day mortality between nonsevere COVID-19 patients treated and untreated with convalescent plasma. Clinical Trials Registration. NCT04545047.Keywords
Funding Information
- Department of Veterans Affairs (VA) Office of Research and Development
- VA-CAUSAL Methods Core
- VA Boston Healthcare System
- VA Puget Sound Healthcare System
- VA Informatics and Computing Infrastructure (VA HSR RES 13–457)
- Department of Veterans Affairs
This publication has 31 references indexed in Scilit:
- Kinetics of viral load and antibody response in relation to COVID-19 severityJCI Insight, 2020
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19JAMA, 2020
- Autoinflammatory and autoimmune conditions at the crossroad of COVID-19Journal of Autoimmunity, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Interpreting Diagnostic Tests for SARS-CoV-2JAMA, 2020
- Convalescent plasma in Covid-19: Possible mechanisms of actionAutoimmunity Reviews, 2020
- A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart StudyBMC Medical Research Methodology, 2016
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- Observational Studies Analyzed Like Randomized ExperimentsEpidemiology, 2008